Pre-print
A deep learning-based iterative digital pathology annotation tool...
2021
News & Events
Get the latest news and updates from ImmunityBio
Related Research
Our therapies are tailored to each patient’s needs. We employ a “triangle” offense designed to deliver durable, complete responses in cancer and infectious diseases.
ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.
EL SEGUNDO, Calif. –Sep. 21, 2020– NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Patrick Soon-Shiong, M.D., Chairman and CEO, will present at the virtual Jefferies Cell Therapy Summit on Tuesday, October 6, 2020 at 12:50 PM ET. The conference presentation will be available…
Both companies agree to share equally in costs relating to COVID-19 therapeutics and vaccine candidates globally; global net profits to be shared 60%/40% in favor of the company contributing the product EL SEGUNDO and CULVER CITY, Calif., August 24, 2020– NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and…
CBR to Provide Umbilical Cord-Derived Cellular Material to NantKwest for additional COVID-19 Clinical Trials Utilizing MSC Therapy Los Angeles, Calif., and El Segundo, Calif., August 10, 2020 – CBR® by Generate Life Sciences, the world’s largest private newborn stem cell bank, and NantKwest (Nasdaq: NK), a clinical-stage, natural killer cell-based immunotherapy…
Preclinical results show this next generation Adeno (hAd5) vaccine, which targets both spike (S) and nucleocapsid (N) SARS-CoV-2 proteins, generates CD4+ and CD8+ T-cell responses, both of which can form long-term immune memory. Inclusion of nucleocapsid in this vaccine construct potentially overcomes the risk of emerging mutations in spike, which might limit…
EL SEGUNDO, Calif — Jun. 29, 2020– NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, announced today the closing of its previously announced underwritten public offering of an aggregate of 8,521,500 shares of its common stock (4,811,500 shares at a price to the public of $9.50 per…
EL SEGUNDO, Calif.–Jun. 25, 2020– NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the pricing of an underwritten public offering of an aggregate of 7,410,000 shares of its common stock (3,700,000 shares at a price to the public of $9.50 per share and 3,710,000 shares…
EL SEGUNDO, Calif.—Jun. 24, 2020– NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, NantKwest expects to grant the underwriters a…
Download the Presentation (PDF) View the PowerPoint Presentaion
San Francisco on Monday, January 7th Download the Presentation (PDF) View the PowerPoint Presentaion Listen to the Webcast
Culver City and San Diego, CA April 4, 2017 - NantKwest, Inc. (Nasdaq:NK)
CULVER CITY, Calif.--Mar. 20, 2017-- NantKwest, Inc. (Nasdaq:NK),
CULVER CITY, Calif.--(BUSINESS WIRE)--Jan. 23, 2017-- NantKwest Inc. (Nasdaq:NK),
December 19, 2016 — Culver City, California — NantKwest (Nasdaq:NK),
NEW YORK (GenomeWeb) – Consumer genomics firm Genos announced
Culver City, November 21, 2016 NantKwest Inc.
CULVER CITY, Calif.--Nov. 14, 2016-- NantKwest Inc.
Culver City, November 8, 2016 NantKwest Inc. (Nasdaq:NK),
CULVER CITY, Calif.–(BUSINESS WIRE)–Sep. 10, 2016– NantKwest, Inc (NASDAQ:NK),
Dr. Patrick Soon-Shiong is welcomed by Pope Francis
Culver City, May 9, 2016 -- NantKwest, Inc (Nasdaq:NK), today announced
CULVER CITY, Calif. – April 20, 2016
Culver City, California, April 15, 2016—NantKwest Inc.
Culver City, California, April 5, 2016—NantBioScience, Inc.,
CULVER CITY, Calif. – March 22, 2016 – Cancer Moonshot 2020
CULVER CITY, CALIFORNIA-(BUSINESS WIRE), MARCH 4, 2016 NantKwest (Nasdaq:NK) and NantHealth
Soon-Shiong taps biotech hub for talent, biomedical manufacturing prowess By Bradley J. Fikes | 3:33 p.m. March 3, 2016
“Culver City, CA, December 22, 2015 – NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy
“Novel protocol combining metronomic Nant-paclitaxel with HER2-targeted natural killer cells
NantKwest, Inc (Nasdaq:NK) NantKwest today announced that the company will be presenting at the
Stephen Farrand, Ph.D., former Merck executive appointed Senior Vice
--Company Adds Clinical Development, Medical Affairs and M&A Executives--
NantKwest, Inc. (formerly Conkwest, Inc.) (Nasdaq: NK), a clinical-stage immunotherapy
NantKwest, Inc. (formerly Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing
NantKwest, Inc. (formerly known as Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing
NantKwest, Inc., a clinical-stage immunotherapy company focused on harnessing the power of the innate immune